proteases Inhibitors
5 drugsAbout proteases
Proteases, also known as peptidases or proteinases, are enzymes catalyzing the breakdown of proteins into smaller peptides or amino acids. They play critical roles in digestion, blood clotting, immune responses, and cell signaling. Their essential function makes them important players in a vast array of biological processes.
Proteases have emerged as important drug targets, though no genetic evidence directly links them to specific diseases. The success of existing protease-targeting therapies underscores their therapeutic potential. Modulation of proteases holds promise for developing novel treatments across a spectrum of diseases.
Five FDA-approved drugs, including CREON, ZENPEP, VIOKACE, PERTZYE, and PANCREAZE, target proteases. All five drugs are biologics classified as 'other'. These drugs are marketed by five companies, including AbbVie and EURAND PHARMA LTD.
Top proteases Drugs
The competitive landscape includes five companies with approved drugs, such as AbbVie and EURAND PHARMA LTD.
The presence of multiple companies indicates a moderately competitive market with potential entry barriers.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| PERTZYE | DIGESTIVE CARE INC | 2012 | 1 |
| CREON | AbbVie | 2009 | 1 |
proteases Drug Modality Landscape
Modalities
Routes of Administration
proteases requires biologic approaches (enzyme), likely due to its structure or location.
The exclusive use of biologics suggests an opportunity for small molecule protease inhibitors.
proteases Clinical Trials 23 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on proteases. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 0 | 3 | 1 | 0% |
| Phase 2 | 6 | 1 | 2 | 3 | 33% |
| Phase 3 | 2 | 1 | 1 | 0 | 50% |
| Phase 4 | 11 | 4 | 6 | 1 | 40% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
proteases Drug Approval Timeline (2009 - 2012)
The first protease-targeting drug was approved in 2009 (CREON), and the most recent in 2012 (PERTZYE).
The short approval span suggests a potentially saturated market or challenges in developing new protease-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on proteases. A trial counts if an approved drug acting on proteases is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.